Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-02T19:11:03.840Z Has data issue: false hasContentIssue false
  • English
  • Français

Influences upon the diffusion of thrombolysis for acute myocardial infarction in England: Case study

Published online by Cambridge University Press:  01 November 2004

Alison Cook ,
Claire Packer ,
Andrew Stevens  and
Tom Quinn
Alison Cook
Affiliation:
The University of Birmingham
Claire Packer
Affiliation:
The University of Birmingham
Andrew Stevens
Affiliation:
The University of Birmingham
Tom Quinn
Affiliation:
Coventry University
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: To investigate the factors that influenced the adoption and diffusion of thrombolysis in acute myocardial infarction in England and to verify usage data from 1981 to 2001.

Methods: Survey of cardiologists in England using a pre-prepared time line of historical events and a plot of thrombolysis diffusion since 1981. The cardiologists were divided into three groups that were provided with (i) the time line only, (ii) the diffusion curve only, and (iii) the time line and the diffusion curve.

Results: The GISSI and ISIS-2 clinical trials were perceived to have had a significant influence upon the initial diffusion of thrombolysis in England occurring over the 3 years after launch. Other positive influences included the initial listing in the national formulary, the change to administration in emergency departments, the rise in evidence-based medicine, and production of national guidance.

Conclusions: Although it is apparent that the overall influences on adoption and diffusion of thrombolysis were multiple; clinical trials, service developments, and national guidelines all were judged to have played a part. The GISSI and ISIS-2 clinical trials were confirmed as the major influence on initial adoption.

Keywords

Thrombolytic therapyMyocardial infarctionDiffusion of innovation
Type
GENERAL ESSAYS
Information
International Journal of Technology Assessment in Health Care , Volume 20 , Issue 4 , November 2004 , pp. 537 - 544
Copyright
© 2004 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. 1992; A comparison of results of meta-analyses of randomised control trials and recommendations of clinical experts. JAMA. 268: 240– 248.Google Scholar
Bonnair A, Persson J. 1996: Innovation and diffusion of health care technologies. In: Szcepura A, Kankaanpää J, eds. Assessment of health care technologies. Chichester: Wiley; 17– 28.
Col NF, McLaughlin TJ, Soumerai SB, et al. 1996; The impact of clinical trials on the use of medications for acute myocardial infarction. Arch Intern Med. 156: 54– 60.Google Scholar
DeWood MD, Spores J, Notske R, et al. 1980; Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 303: 897– 902.Google Scholar
Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. 1958; The treatment of patients suffering from early myocardial infarction with massive and prolonged streptokinase therapy. Transcripts Assoc Am Physicians. 71: 287– 296.Google Scholar
1986; Gruppo italiano per lo studio della streptochinasi nell'infarcto miocardio (GISSI). Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet. i: 397– 402.
Herrick JB. 1912; Clinical features of sudden obstruction of coronary arteries. JAMA. 59: 2015– 2020.Google Scholar
Hood S, Birnie D, Swan L, Hills WS. 1998; Questionnaire survey of thrombolytic treatment in accident and emergency departments in the United Kingdom. BMJ. 316: 274.Google Scholar
Hummel MJ, van Rossum W, Verkerke GJ, Rakhorst G. 2000; Assessing medical technologies in development. A new paradigm of medical technology assessment. Int J Technol Ass Health Care. 16: 1214– 1219.Google Scholar
1987; ISIS Steering Committee. Intravenous streptokinase given within 0-4 hours of onset of myocardial infraction reduced mortality in ISIS-2. Lancet. i: 502.
1988; ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. ii: 349– 60.
Ketley D, Woods KL. 1993; Impact of clinical trials in clinical practice: Example of thrombolysis for acute myocardial infarction. Lancet. 342: 891– 894.Google Scholar
Ketley D. 1996. Beyond clinical trials: Translation of evidence into practice in the treatment of acute myocardial infarction [dissertation]. Leicester University;
Lamas GA, Peeffer MA, Hamm P, et al. 1992; for the SAVE investigators. Do the results of randomised clinical trials of cardiovascular drugs influence medical practice. N Engl J Med. 327: 241– 247.Google Scholar
Lau J, Antman E, Jimenez-Silva J, et al. 1992; Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 327: 248– 254.Google Scholar
Pell ACH, Miller HC, Robertson CE, Fox KAA. 1992; Effect of ‘fast track’ admission for acute myocardial infarction on delay to thrombolysis. BMJ. 304: 83– 87.Google Scholar
Petch MC. 2002 Heart disease, guidelines, regulations, and the law. Heart. 87: 472– 479.Google Scholar
Raftery J, Stevens A, Roderick P. 2001: The potential use of routine datasets in health technology assessment. In: Stevens A, Abrams K, Brazier J, Fitzpatrick R, Lilford R, eds. The advanced handbook of methods in evidence based healthcare. London: Sage Publications; 136– 148.
White HD, Van de Werf F. 1998; Thrombolysis for acute myocardial infarction. Circulation. 97: 1632– 1646.Google Scholar

REFERENCES FOR BOX 1

1988; AIMS Trial Study Group. Effects of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet. i: 545– 549.
Antman EM, Lau J, Kupelnick B, Mosteller F, Chalmers TC. 1992; A comparison of results of meta-analyses of randomised control trials and recommendations of clinical experts. JAMA. 268: 240– 248.Google Scholar
1992 Birkhead JS on behalf of the joint committee of the British Cardiac Society and a cardiology committee of Royal College of Physicians of London. Time delays in provision of thrombolytic treatment in six district hospitals. BMJ. 305: 445– 448.
1997; Birkhead JS on behalf of the Myocardial Infarction Audit Group. Thrombolytic treatment for myocardial infarction: An examination of practice in 39 UK hospitals. Heart. 78: 28– 33.
1999; Birkhead JS on behalf of the Myocardial Infraction Audit Group. Trends in the provision of thrombolytic treatment between 1993 and 1997. Heart. 82: 438– 442.
Boersma E, Maas ACP, Deckers JW, Simoons ML. 1996; Early thrombolytic therapy in acute myocardial infarction: Reappraisal of the golden hour. Lancet. 348: 771– 775.Google Scholar
Burns JMA, Hogg KJ, Rae AP, Hillis WS, Dunn FG. 1989; Impact of a policy of direct admission to a coronary care unit on use of thrombolytic treatment. Br Heart J. 61: 322– 325.Google Scholar
1996; Committee on Management of Acute Myocardial Infarction. ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 28: 1328– 1428.
Committee on Management of Acute Myocardial Infarction. 1999 Update: ACC/AHA guidelines for the management of patients with acute myocardial infraction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Available at: www.acc.or.
Davies MJ, Bland JM, Hangartner JRW, Angelini A, Thomas AC. 1989; Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J. 10: 203– 208.Google Scholar
De Bono DP, Hopkins A. 1994; The management of acute myocardial infarction: Guidelines and audit standards. Report of a workshop of the Joint Audit Committee of the British Cardiac Society and the Royal College of Physicians. J R Coll Physicians. 28: 312– 317.Google Scholar
1995. Dear to Our Hearts? Commissioning services for the treatment and prevention of coronary heart disease. Audit Commission;
DeWood MD, Spores J, Notske R, et al. 1980; Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 303: 897– 902.Google Scholar
1993; EMERAS (Estudio Multicentrico Estretoquinasa Republicas de America del Sur) Collaborative Group. Randomised trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet. 342: 767– 772.
1994; Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview or early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 343: 311– 322.
1992; GREAT Group. Feasibility, safety, and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. BMJ. 305: 548– 553.
1990; Gruppo Italiano per lo studio della sopravvivenza nell'infarto miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 336: 66– 71.
1986; Gruppo italiano per lo studio della streptochinasi nell'infarcto miocardio (GISSI). Effectiveness of intravenous thrombolytic therapy in acute myocardial infarction. Lancet. i: 397– 402.
Hannaford P, Vincent R, Ferry S et al. 1995; Assessment of the practicality and safety of thrombolysis with anistreplase given by general practitioners. Br J Gen Pract. 45: 175– 179.Google Scholar
Harrop SN. 1998; Can paramedics help accelerate thrombolysis in myocardial infarction? Prehosp Immediate Care. 2: 18– 24.Google Scholar
Hood S, Birnie D, Swan L, Hills WS. 1998; Questionnaire survey of thrombolytic treatment in accident and emergency departments in the United Kingdom. BMJ. 316: 274.Google Scholar
1988; ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. ii: 349– 360.
1992; ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 339: 753– 770.
1993; LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6–24 hours after onset of acute myocardial infarction. Lancet. 342: 759– 766.
Lau J, Antman E, Jimenez-Silva J, et al. 1992; Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 327: 248– 254.Google Scholar
2002. National Institute for Clinical Excellence. Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction. London: National Institute for Clinical Excellence;
2000. National Service Framework for Coronary Heart Disease. London: Department of Health; Available at: www.doh.gov.uk/nsf/coronary.ht.
1998. National Service Framework on Coronary Heart Disease—Emerging findings report. London: Department of Health; Available at: www.doh.gov.uk/pub/docs/doh/coronary.pd.
Pell ACH, Miller HC, Robertson CE, Fox KAA. 1992; Effect of ‘fast track’ admission for acute myocardial infarction on delay to thrombolysis. BMJ. 304: 83– 87.Google Scholar
Quinn T. 1995; Can nurses safely assess suitability for thrombolytic therapy? A pilot study. Intensive Crit Care Nurs. 11: 126– 129.Google Scholar
Rawles J. 1997; Pre-hospital coronary care. Prehosp Immediate Care. 1: 12– 18.Google Scholar
1999. Review of prescribing, supply and administration of medicines.The Crown Report. London: Department of Health; Available at: www.doh.gov.uk/prescrib.ht.
Round A, Marshall AJ. Survey of general practitioners' prehospital management of suspected acute myocardial infarction. BMJ. 309: 375– 376.
Rowley JM, Mounser P, Harrison EA, Skene AM, Hampton JR. 1998; Management of myocardial infarction: Implications for current policy derived from the Nottingham Heart Attack Register. Br Heart J. 67: 255– 262.Google Scholar
1993; The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med. 329: 383– 389.
1993; The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329: 1615– 1622.
1993; The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329: 673– 682.
2001; The GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinoloytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet. 357: 1905– 1914.
1992. The health of the nation: A strategy for health in England. London: HMSO;
1986; The I.S.A.M Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M). Mortality, morbidity, and infarct size at 21 days. N Engl J Med. 314: 1465– 1471.
2000. The NHS plan. London: HMSO; Available at: www.nhs.uk/nationalpla.
1996; The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Acute myocardial infarction: Pre-hospital and in-hospital management. Eur Heart J. 17: 43– 63.
Weaver WD, Cerqueira M, Hallstrom AP, et al. 1993; Prehospital-initiated vs hospital-initiated thrombolytic therapy. The myocardial infarction triage and intervention trial. JAMA. 270: 1211– 1216.Google Scholar
Weston CFM, Penny WJ, Julian DG. 1994; Guidelines for the early management of patients with myocardial infarction. BMJ. 308: 767– 771.Google Scholar
Wilcox RG, Von der Lippe G, Olsson CG, et al. 1988; Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet. 2: 525– 530.Google Scholar